Home West Coast Seattle, WA BrainChild Bio COMPANY
Clinical Phase 2
7 open jobs · last seen Oct 23, 2026 · 2 sources
Keywords: oncology neurology tumors solid tumor cell therapy Diffuse Intrinsic Pontine Glioma DIPG Brain Tumor CNS Tumor Central Nervous System Tumor Childhood CNS Tumor Adult CNS Tumor Brainstem Glioma Diffuse Midline Glioma BCB-276 Show all 15 keywords
Profile checked Oct 10, 2026
Hiring Title Location (from posting) Employer posted First seen Specialist, Cell Therapy Patient Operations - 6 month contractor role United States Oct 20, 2026 Oct 21, 2026 Senior Research Associate - Process Development Seattle, WA Oct 20, 2026 Oct 21, 2026 Research Associate - Process Development Seattle, WA Oct 20, 2026 Oct 21, 2026 Director, Program Lead Seattle, WA Oct 6, 2026 Oct 11, 2026 Director, CMC Quality United States Aug 27, 2026 Oct 11, 2026
See all 7 jobs
At a glance Region West Coast Stage Clinical Phase 2 Latest trial Phase 2: Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse… (2026-08) source Raises and deals from press releases Raises announced in these releases: $116M disclosed.
From the company’s own releases; this list is partial. All raises and deals
Timeline Sep 8, 2026 Raise Private equity round — Series A: $116M (total, as published), announced Sep 8, 2026. Source: company release on GlobeNewswire. source ↗ Sep 8, 2026 Raise Series A · $116M source ↗ 2026-08 Trial start Phase 2: Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG). source ↗ Upcoming milestones 2028-10 (ESTIMATED) · Phase 2 · Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG). · NCT07680439 Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding Raised: $116.0M. Last 2 years.
Sep 8, 2026 Private equity round — Series A: $116M (total, as published), announced Sep 8, 2026. Source: company release on GlobeNewswire. source ↗ Clinical trials (lead sponsor) 1 Record Title Phase Status Start Primary completion NCT07680439 Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG). Phase 2 Recruiting 2026-08 2028-10 (estimated)
Open jobs 7 Title Location (from posting, not HQ) Employer posted First seen Level Specialist, Cell Therapy Patient Operations - 6 month contractor role United States Oct 20, 2026 Oct 21, 2026 Not stated Senior Research Associate - Process Development Seattle, WA Oct 20, 2026 Oct 21, 2026 Not stated Research Associate - Process Development Seattle, WA Oct 20, 2026 Oct 21, 2026 Not stated Director, Program Lead Seattle, WA Oct 6, 2026 Oct 11, 2026 Senior Description Director, CMC Quality United States Aug 27, 2026 Oct 11, 2026 Senior Description Process Engineer Seattle, WA Aug 12, 2026 Oct 11, 2026 Mid Description Director, Regulatory Affairs, CMC United States Jul 15, 2026 Oct 11, 2026 Senior Description
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
Connect See your connections at BrainChild Bio on LinkedIn (search by name, results not checked) LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.
LinkedIn page linked from the company's own site: source · seen 2026-10-18